Upon entering the tumor, under hypoxic conditions, R848 can be released from its hypoxia-sensitive linker, further enhancing antitumor immunity by reprogramming tumor-associated macrophages (TAMs), suppressing myeloid-derived suppressor cells (MDSCs), and boosting cytotoxic CD8+ T-cell responses. This evidence concerns the gene CD8A and neoplasm.